FDA inspection

Enzon Pharmaceuticals, Inc: FDA inspection ending Jun 20, 2002

FDA inspection 221359 · Voluntary Action Indicated (VAI) · South Plainfield, NJ

Key facts

Inspection ID 221359
Firm Enzon Pharmaceuticals, Inc
FEI number 2245253
Address 300 Corporate Ct
City South Plainfield
State NJ
ZIP 07080-2415
Fiscal year 2002
Inspection end date Jun 20, 2002
Classification Voluntary Action Indicated (VAI)
Project area Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance
Product type Biologics, Drugs

At a glance

  • None Citations
  • 1–9 Posted citations
  • No Warning letter followed
  • Yes Form FDA 483 issued
  • No Establishment inspection report (EIR) exists
  • 10–99 Inspections at this FEI

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About FDA inspections

FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.

Source: U.S. Food and Drug Administration (FDA), inspection classification data

Browse all FDA inspections